This article was originally published on ETFTrends.com.
Whether the markets are roaring or experiencing doldrums, health care exchange-traded funds (ETFs) have been a paragon of reliability, but the sector could soon get tested with a forthcoming wave of government regulation. In particular, the pharmaceutical business is experiencing a profit squeeze as a result of lesser-than-expected revenue from the sale of generic drugs. [...]
Continue Reading Below